IL-1β通过促进JAK2突变造血干细胞早期克隆扩增推动骨髓增殖性肿瘤疾病起始
研究利用JAK2-V617F与GFP双转基因小鼠骨髓移植模型,并与IL-1β-/-或IL-1R1-/-小鼠杂交,通过高稀释竞争性骨髓移植(每受体仅1至3个造血干细胞)探讨IL-1β对MPN克隆演化的作用。结果显示JAK2突变造血干细胞缺失IL-1β可降低植入、限制克隆扩增、减少功能性造血干细胞总数并降低向MPN转化率;受体缺失IL-1R1亦降低MPN转化率但不减少JAK2突变造血干细胞植入频率;抗IL-1β抗体可保留间充质基质细胞高频并降低植入率与MPN转化率。
要点
- JAK2突变造血干细胞缺失IL-1β降低植入、限制克隆扩增并降低向MPN转化率。
- 受体缺失IL-1R1降低MPN转化率但不减少JAK2突变造血干细胞植入频率。
- 抗IL-1β抗体保留间充质基质细胞高频并降低植入率与MPN转化率。
核心结论
- IL-1β是阻止JAK2-V617F意义未明克隆性造血向MPN转化的潜在治疗靶点。
研究设计与样本
- 研究采用JAK2-V617F与GFP双转基因(VF;GFP)小鼠骨髓移植,并与IL-1β-/-或IL-1R1-/-小鼠杂交。
- 进行高稀释竞争性骨髓移植,每受体仅1至3个造血干细胞,以研究IL-1β及其受体对MPN单克隆演化的作用。
主要发现
- JAK2突变造血干细胞缺失IL-1β降低植入、限制克隆扩增、降低功能性造血干细胞总数并降低向MPN转化率。
- 受体缺失IL-1R1降低向MPN转化率,但不减少JAK2突变造血干细胞的植入频率。
- 发生MPN的VF;GFP骨髓移植野生型受体IL-1β水平升高且间充质基质细胞频率降低。
- 未发生MPN、IL-1β仅轻度升高且GFP嵌合率低(类似CHIP)的受体中间充质基质细胞频率亦降低。
- 抗IL-1β抗体保留VF;GFP受体中间充质基质细胞高频,并降低植入率与向MPN转化率。
临床怎么用
- 作者认为IL-1β是阻止JAK2-V617F意义未明克隆性造血向MPN转化的潜在治疗靶点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
JAK 2-V617F is the most frequent somatic mutation causing myeloproliferative neoplasm (MPN). JAK2-V617F can be found in healthy individuals with clonal hematopoiesis of indeterminate potential (CHIP) with a frequency much higher than the prevalence of MPNs. The factors controlling the conversion of JAK2-V617F CHIP to MPN are largely unknown. We hypothesized that interleukin-1β (IL-1β)-mediated inflammation can favor this progression. We established an experimental system using bone marrow (BM) transplantations from JAK2-V617F and GFP transgenic (VF;GFP) mice that were further crossed with IL-1β-/- or IL-1R1-/- mice. To study the role of IL-1β and its receptor on monoclonal evolution of MPN, we performed competitive BM transplantations at high dilutions with only 1 to 3 hematopoietic stem cells (HSCs) per recipient. Loss of IL-1β in JAK2-mutant HSCs reduced engraftment, restricted clonal expansion, lowered the total numbers of functional HSCs, and decreased the rate of conversion to MPN. Loss of IL-1R1 in the recipients also lowered the conversion to MPN but did not reduce the frequency of engraftment of JAK2-mutant HSCs. Wild-type (WT) recipients transplanted with VF;GFP BM that developed MPNs had elevated IL-1β levels and reduced frequencies of mesenchymal stromal cells (MSCs). Interestingly, frequencies of MSCs were also reduced in recipients that did not develop MPNs, had only marginally elevated IL-1β levels, and displayed low GFP-chimerism resembling CHIP. Anti-IL-1β antibody preserved high frequencies of MSCs in VF;GFP recipients and reduced the rate of engraftment and the conversion to MPN. Our results identify IL-1β as a potential therapeutic target for preventing the transition from JAK2-V617F CHIP to MPNs.
引用
- Rai S, Zhang Y, Grockowiak E, et al. IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells. Blood Adv. 2024. PMID: 38207211. doi:10.1182/bloodadvances.2023011338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。